Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome

This study has been completed.
Eli Lilly and Company
Information provided by:
Mclean Hospital Identifier:
First received: November 16, 2006
Last updated: August 6, 2010
Last verified: August 2010

We hypothesize that duloxetine treatment will be associated with improvement in symptoms of IBS, particularly abdominal pain, in individuals without comorbid major depressive disorder.

During this 12-week, open-label, outpatient study, male and female subjects between the ages of 18 and 65 years who have been diagnosed with irritable bowel syndrome (IBS) will be treated with open-label duloxetine.

Condition Intervention Phase
Irritable Bowel Syndrome
Drug: duloxetine
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome Without Comorbid Major Depressive Disorder

Resource links provided by NLM:

Further study details as provided by Mclean Hospital:

Primary Outcome Measures:
  • Abdominal Pain, as Determined by Daily Pain Diaries (Patterned After Item 3 From the Brief Pain Inventory; Cleeland and Ryan, 1994). [ Time Frame: baseline and week 12 ]
    Subjects rated abdominal pain daily on a scale of 0-10 (0 being no pain and 10 being worst pain). The pain score at each visit represented the mean score from all days since the previous visit.

Secondary Outcome Measures:
  • Brief Pain Inventory [ Time Frame: At each visit ]
  • Short Form McGill Pain Questionnaire [ Time Frame: At each visit ]
  • Clinical Global Impression Scale [ Time Frame: At each visit ]
  • Hamilton Depression Rating Scale [ Time Frame: At first visit only ]
  • Hamilton Anxiety Rating Scale [ Time Frame: At visits 2, 5, 7, and 9 ]
  • Irritable Bowel Syndrome-Quality of Life Scale [ Time Frame: At each visit ]
  • Sheehan Disability Scale [ Time Frame: At each visit ]

Enrollment: 15
Study Start Date: November 2006
Study Completion Date: February 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
12-week, open-label trial of duloxetine in subjects with IBS.
Drug: duloxetine
30mg oral duloxetine per day for one week, titrated up to 60mg per day at day 8, concluded by a one week taper period of 4 days of 30mg pills at the conclusion of the study, followed by 3 days on no medication (4+3 days=1 week), concluded with a post-taper follow-up appointment with a study physician.
Other Name: Cymbalta

Detailed Description:

IBS is a chronic gastrointestinal disorder characterized by abdominal pain, altered bowel habits, and abdominal bloating for which no organic cause can be determined. Duloxetine has demonstrated efficacy in the treatment of depression as well as in several pain syndromes including diabetic peripheral neuropathy and fibromyalgia. We hypothesize that it will be a safe and efficacious treatment for the symptoms of IBS, in particular abdominal pain.

We plan to study 15 male and female subjects between the ages of 18 and 65 years who have had gastrointestinal symptoms at least 2 days/week for greater than six months and who have been diagnosed with IBS by a physician. During the 12-week study, subjects will receive open-label duloxetine titrated up to 60mg/day. Subjects will be asked to complete a total of ten study visits during the 12-week study period. All study visits will be conducted at McLean Hospital.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18-65 years of age
  • Subjects must have been diagnosed with irritable bowel syndrome by a physician
  • Subjects must have had gastrointestinal symptoms for 2 or more days per week for > 6 months

Exclusion Criteria:

  • Lifetime history of bipolar disorder, psychotic disorder, or obsessive-compulsive disorder
  • Current (within past 6 months) diagnosis of major depressive disorder or substance abuse disorder
  • Active suicidal/homicidal ideation
  • Pregnant women or women of child-bearing potential not using an approved methods of contraception
  • Individuals with an unstable medical condition that in the opinion of the investigator would interfere with the interpretation of symptoms
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00401258

United States, Massachusetts
McLean Hospital
Belmont, Massachusetts, United States, 02478
Sponsors and Collaborators
Mclean Hospital
Eli Lilly and Company
Principal Investigator: Brian P Brennan, MD Mclean Hospital
  More Information

Responsible Party: Brian P. Brennan, M.D., McLean Hospital Identifier: NCT00401258     History of Changes
Other Study ID Numbers: 2006-P-001723
Study First Received: November 16, 2006
Results First Received: June 25, 2010
Last Updated: August 6, 2010

Keywords provided by Mclean Hospital:
irritable bowel syndrome
irritable bowel

Additional relevant MeSH terms:
Irritable Bowel Syndrome
Pathologic Processes
Colonic Diseases, Functional
Colonic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Duloxetine Hydrochloride
Serotonin and Noradrenaline Reuptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Antidepressive Agents
Psychotropic Drugs
Dopamine Agents processed this record on April 25, 2017